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X-linked juvenile retinoschisis (XLRS, MIM 312700) is a common early onset macular degeneration in
males characterized by mild to severe loss in visual acuity, splitting of retinal layers, and a reduction in
the b-wave of the electroretinogram (ERG). The RS1 gene (MIM 300839) associated with the disease
encodes retinoschisin, a 224 amino acid protein containing a discoidin domain as the major structural
unit, an N-terminal cleavable signal sequence, and regions responsible for subunit oligomerization.
Retinoschisin is secreted from retinal cells as a disulphide-linked homo-octameric complex which binds
to the surface of photoreceptors and bipolar cells to help maintain the integrity of the retina. Over 190
disease-causing mutations in the RS1 gene are known with most mutations occurring as
non-synonymous changes in the discoidin domain. Cell expression studies have shown that disease-
associated missense mutations in the discoidin domain cause severe protein misfolding and retention
in the endoplasmic reticulum, mutations in the signal sequence result in aberrant protein synthesis, and
mutations in regions ﬂanking the discoidin domain cause defective disulphide-linked subunit assembly,
all of which produce a non-functional protein. Knockout mice deﬁcient in retinoschisin have been
generated and shown to display most of the characteristic features found in XLRS patients. Recombinant
adeno-associated virus (rAAV) mediated delivery of the normal RS1 gene to the retina of young knockout
mice result in long-term retinoschisin expression and rescue of retinal structure and function providing
a ‘proof of concept’ that gene therapy may be an effective treatment for XLRS.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.Contents
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X-linked juvenile retinoschisis (XLRS, MIM 312700) is a rela-
tively common early onset retinal degenerative disease that affects
males early in life. Characteristic features include mild to severe
loss in central vision, radial streaks arising from foveal schisis,
splitting of inner retinal layers in the peripheral retina, and
a negative electroretinogram (ERG) arising from a marked reduc-
tion in b-wave amplitude (George et al., 1995; Tantri et al., 2004).
Disease progression and severity is highly variable even within
families. During the course of the disease, secondary complications
including retinal detachment and vitreous hemorrhage can occur
leading to a poor outcome. Female carriers are asymptomatic
although detailed clinical examination can reveal minor retinal
abnormalities (Kim et al., 2007).
XLRS was ﬁrst thought to arise as a result of inherited defects in
Müller cells. This was based on the b-wave response which was
originally thought to directly involve Müller cells and histological
examination of retina tissue from deceased patients showing
ﬁlamentous material merging with Müller cell membrane and
splitting of the nerve ﬁber layer (Condon et al., 1986; Gass, 1999;
Miller and Dowling, 1970; Yanoff et al., 1968). Identiﬁcation of the
gene responsible for XLRS in 1997 by Sauer et al. (1997) and the
subsequent analysis of gene and protein expression in the retina,
however, have directly implicated photoreceptors and bipolar cells,
and not Müller cells, in the disease process (Grayson et al., 2000;
Moldayet al., 2001;Mooyet al., 2002; Reid et al.,1999). TheRS1 gene
encodes a 24 kDa discoidin-domain containing protein which is
secreted as a homo-oligomeric complex (Sauer et al.,1997;Wu et al.,
2005). This complex binds tightly to the surface of photoreceptors
and bipolar cellswhere it helps tomaintain the cellular organization
of the retina and structure of the photoreceptor-bipolar synapse.
Over the past 15 years signiﬁcant progress has been made in
understanding XLRS at a clinical, genetic, molecular, and cellular
level. To date 191 different mutations in the RS1 gene are known to
cause XLRS. Protein expression studies have provided insight into
the mechanisms by which speciﬁc mutations affect the expression,
structure and secretion of retinoschisin and lead to a pathogenic
state. Mice deﬁcient in retinoschisin have been developed and used
to obtain insight into the role of retinoschisin in retina structure,
function and pathology. Finally, the delivery of the normal RS1 gene
to knockout mice deﬁcient in endogenous retinoschisin has
resulted in signiﬁcant restoration of retinal structure and function.
In this chapter, we review our current knowledge of retinoschisin
and its role in XLRS pathology from a clinical, genetic andmolecular
perspective.2. Clinical ﬁndings of congenital XLRS
2.1. Clinical manifestations
XLRS was ﬁrst described in 1898 in two affected brothers by the
Austrian ophthalmologist Josef Haas (Haas, 1898). Since then, XLRS
has been shown to be one of the more frequent inherited retinal
disorders affecting macular function in males with an estimated
prevalence ranging between 1:5000 to 1:20,000 (George et al.,
1995). The name derives from an internal splitting of the retina
mostly affecting the temporal periphery of the fundus. This
peripheral retinoschisis occurs in less than 50% of affected individ-
uals, whereas foveal involvement is present in all affected patients.
Foveal involvement is usually associated with moderate visual loss.
Therefore, XLRS is frequently diagnosed prior to school age
suggesting a juvenile onset. Several cases of severe retinoschisis
have been described in the ﬁrst year of age suggesting that XLRS
indeed is present at birth (Lee et al., 2009; Prasad et al., 2006; Renner
et al., 2008; Sieving,1998). These severe cases aswell as the absence
of acute visual loss in themajority of cases indicates that the onset of
XLRS is congenital, but thediagnosis is delayedbecause small infants
are not affected in their daily tasks by moderate visual loss.
Multiple studies reporting clinical features of XLRS in a series of
families have been reported world-wide (Apushkin et al., 2005b;
Atchaneeyasakul et al., 2010; Eksandh et al., 2000; Forsius et al.,
1963; George et al., 1995, 1996; Hewitt et al., 2005; Kellner et al.,
1990; Lesch et al., 2008; Pimenides et al., 2005; Renner et al.,
2008; Riveiro-Alvarez et al., 2009; Shinoda et al., 2000; Shukla
et al., 2007; Simonelli et al., 2003; Vainio-Mattila et al., 1969; Xu
et al., 2011). The penetrance of XLRS is almost complete but
clinical expression is highly variable (Sieving, 1998). In our series of
100 XLRS patients the manifestations ranged from almost complete
retinoschisis at the age of 3 months in both eyes to normal visual
acuity with mild pigmentary macular abnormalities and a negative
full-ﬁeld electroretinogram (ERG) (Kellner et al., 1990; Renner et al.,
2008). The expression of the disease is usually symmetrical in both
eyes, however, a marked asymmetry of visual function can be
present especially in cases where additional complications occur
(Tantri et al., 2004). Visual acuity is reduced to 20/100 in most
patients although it may vary greatly. On ophthalmoscopy, foveal
retinoschisis presents as a spoke-wheel pattern and peripheral
retinoschisis as a sharply delineated detachment of the inner retinal
sheet usually limited to the periphery or mid-periphery (Fig. 1).
Peripheral retinoschisis may extend from the periphery to the
macula including the fovea in some cases; in rare instances marked
retinoschisis might involve nearly the complete retina. If the inner
Fig. 1. Retina imaging of individuals with XLRS. (a) Severe retinoschisis involving almost the complete retina observed in a boy 3 months of age carrying a RS1-gene p.R213W
mutation. (b) Fundus autoﬂuorescence indicating a spoke-wheel pattern due to overlying foveal retinoschisis in a 12 year old boy carrying a RS1-gene p.R102W mutation. (c) Near-
infrared image of foveal retinoschisis in a 21 year old patient carrying a RS1-gene p.D126_L127delinsE mutation. (d) Spectral domain optical coherence tomography in a 22 year old
male carrying a RS1-gene p.W96G mutation. The upper scan shows marked retinoschisis in different retinal layers. The lower scan after 3 months of local application of dorzolamide
shows a smaller foveal retinoschisis cavity and absence of perifoveal retinoschisis cavities. (e) Color image of peripheral retinoschisis in the lower temporal quadrant of the right eye
in a 20 year old male carrying a RS1-gene p.R209H mutation.
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running free through the vitreous cavity presenting as so-called
vitreous veils. If additional breaks occur in the outer sheet of the
schisis, a retinal detachment may occur.
In the majority of patients, the disease either shows no or
minimal progression (Apushkin et al., 2005b; Kellner et al., 1990;
Kjellstrom et al., 2010; Roesch et al., 1998). Around the age of 30
years, the macular alterations may change from the characteristic
spoke-wheel pattern to unspeciﬁc mild retinal pigment abnor-
malities. In some cases, severe visual loss with increased age has
been described (George et al., 1996) although incidence data are not
available due to the lack of extended long-term follow-up studies.
2.2. Clinical diagnosis
Young boys are often presented for evaluation of bilaterally
reduced visual acuity without acute visual loss. Sudden visual loss
rarely occurs and is often associated with complications like
vitreous hemorrhage or retinal detachment (Lee et al., 2009; Prasad
et al., 2006). Hyperopia is a frequent ﬁnding.
The hallmark of XLRS is the presence of a spoke-wheel pattern
in the macula on high magniﬁcation ophthalmoscopy in patients
younger than 30 years of age (Fig. 1b and c). The spoke-wheel
pattern varies in severity and might be difﬁcult to detect or
exclude especially in young boys with limited cooperation even by
experienced clinicians (Kellner et al., 1990; Sieving, 1998). In
patients older than 30 years the foveal retinoschisis is replaced by
unspeciﬁc mild retinal abnormalities. Peripheral retinoschisis,
mostly in the lower temporal quadrant, is an important diagnostic
sign but is present in less than 50% of affected patients (Fig. 1e).
Additional phenomena, e.g. the Mizou phenomenon or white
ﬂecks, have been observed in few cases of XLRS (Hotta et al., 2001;
Vincent et al., 2009).
Optic coherence tomography (OCT) has changed the diagnostic
approach for XLRS (Apushkin et al., 2005a; Chan et al., 2004;Muscat et al., 2001; Prenner et al., 2006; Renner et al., 2008; Stanga
et al., 2001; Urrets-Zavalia et al., 2007) and nowadays spectral
domain OCT (SD-OCT) is the major diagnostic technique for this
disease (Fig. 1d). Even in an uncooperative child a single scan of the
foveal area is sufﬁcient to detect signs of XLRS and to distinguish
XLRS from other differential diagnosis associated with visual loss in
young boys (Dhingra and Patel, 2010; Eriksson et al., 2004; Renner
et al., 2008). SD-OCT revealed that the area of retinoschisis
markedly extends beyond the ophthalmoscopically visible spoke-
wheel pattern and includes the macular area up to the vascular
arcades (Gerth et al., 2008; Gregori et al., 2009; Yu et al., 2010). This
novel imaging tool is also important for follow-up examinations
and has resolved the long-standing histologic debate in which
retinal layer the retinal splitting occurs (Condon et al., 1986;
Manschot, 1972; Yanoff et al., 1968). Indeed, cystoid changes may
involve various retinal layers from the retinal nerve ﬁber layer to
the nuclear layer (Gerth et al., 2008; Gregori et al., 2009; Yu et al.,
2010). Thinning of the retinal nerve ﬁber layer has been reported in
a series of XLRS patients (Genead et al., 2010). In older patients
SD-OCT might show absence of retinoschisis, retinal thinning and
epiretinal membranes that increases the difﬁculty to differentiate
from other forms of macular dystrophy (Menke et al., 2011).
Fundus autoﬂuorescence (FAF) is frequently used for the
differential diagnosis of retinal dystrophies. XLRS alterations of the
foveal FAF are most likely due to the altered light transmission in
the area of retinoschisis and are a characteristic sign (Fig. 1b),
although the diagnosis should be validated by SD-OCT (Renner
et al., 2008). Fluorescein angiography may reveal retinal pigment
epithelial alterations in older males; but does not contribute to the
differential diagnosis of XLRS.
For several decades the ERG was the major diagnostic technique
for XLRS. The characteristic ERG sign is a so-called ‘negative’ ERG
elicited by a bright ﬂash of light in the dark-adapted retina inwhich
the a-wave is larger than the b-wave in contrast to the normal
ﬁndings. Usually, the light adapted responses show an amplitude
R.S. Molday et al. / Progress in Retinal and Eye Research 31 (2012) 195e212198reduction as well. The origin of the retinal dysfunction is an
abnormality in the ON- and OFF-pathways on the level of the
bipolar cells (Khan et al., 2001). Detailed evaluation of macular
dysfunction with the multifocal electroretinogram (mfERG) has
demonstrated a widespread cone dysfunction as well (Piao et al.,
2003; Sen et al., 2010). A ‘negative’ ERG can be associated with
various retinal disorders (Koh et al., 2001; Renner et al., 2006);
however, in young males the only major differential diagnosis is
congenital stationary night blindness (CSNB) (Bradshaw et al.,
2004). The easier and much faster application of SD-OCT
compared to ERG has diminished the diagnostic role of the ERG
for XLRS. In addition, earlier reports on ERG in XLRS were limited to
patients with clinically manifest XLRS. Recent studies selectively
including patients carrying RS1mutations have shown that the ERG
response is more variable than previously expected (Eksandh et al.,
2005; Renner et al., 2008; Sieving et al., 1999). Most patients
present with an a-wave relatively larger than the b-wave, resulting
in a reduced b/a-ratio, however, a ‘negative’ ERG with a b-wave
smaller than the a-wave is present only in about 50% of the patients
and a relative normal ERG does not exclude the diagnosis of XLRS.
Nevertheless, an ERG is valuable for differential diagnosis in
unexplained visual loss especially in older patients (Koh et al.,
2001; Renner et al., 2006; Sobaci et al., 2007).
Other tests of retinal function, e.g. electro-oculography, color
vision or visual ﬁelds, are of limited diagnostic value. Color vision is
variably abnormal due to affection of the macula and absolute
scotoma which is present in the area of peripheral retinoschisis.
2.3. Findings in carriers
In contrast to other X-linked inherited retinal dystrophies, e.g.
retinitis pigmentosa or choroideremia, female carriers usually have
normal retinal function and rarely present with retinal abnormal-
ities. Only 2/9 obligate carriers of XLRS had functional abnormali-
ties in the mfERG (Kim et al., 2007). Female carriers have rarely
been reported with retinal abnormalities or visual loss (Gieser and
Falls, 1961; Mendoza-Londono et al., 1999; Rodriguez et al., 2005;
Saldana et al., 2007; Wu et al., 1985). Retinal alterations and ERG
abnormalities were variable. Six affected woman were in fact
homozygous carriers of disease mutations (Ali et al., 2003; Forsius
et al., 1963; Saleheen et al., 2008).
2.4. Complications
Vitreous hemorrhages or retinal detachment complicate the
clinical course of XLRS in approximately 5% of all affectedmales and
most frequently develop in the ﬁrst decade of life. Vitreous
hemorrhage mostly clears spontaneously and only rarely requires
vitreous surgery to avoid amblyopia. Results of retinal detachment
surgery are of limited beneﬁt even with advanced surgical tech-
niques (Rosenfeld et al., 1998). Macular holes secondary to XLRS
have rarely been reported (Brasil et al., 2011; Shukla et al., 2006).
2.5. Differential diagnosis
In patients with marked peripheral retinoschisis, disorders with
early onset retinal detachments have to be considered in differ-
ential diagnosis. These include X-linked Norrie syndrome (NS), in
which complete retinal detachment is present at birth and visual
function is nearly absent. NS is associated with mutations in the
Norrie disease gene on Xp11.4 (Berger et al., 1992; Chen et al., 1992).
A less severe variant of NS is the X-linked familial exudative
vitreoretinopathy (FEVR), also associated with mutations in the
Norrie disease gene. Peripheral vascular retinal abnormalities are
present in a variable degree, which may lead to retinal detachment.Similar alterations can be observed in autosomal dominant FEVR
(Criswick-Schepens syndrome) and can be associated with
mutations in frizzled-4 (FZD4) (Robitaille et al., 2002), LRP5
(Toomes et al., 2004), and TSPAN12 (Nikopoulos et al., 2010). The
ophthalmoscopic features in both forms of FEVR are distinct from
XLRS. Incontinentia pigmentii (Bloch-Sulzberger syndrome) can
present with early onset retinal detachment. This syndrome,
however, is a lethal condition in males and is not a differential
diagnosis for XLRS. Other forms of congenital or juvenile retinal
detachment, e.g. following trauma or retinopathy of prematurity,
can usually be excluded by the patient’s history.
In XLRS patients with involvement limited to the fovea other
formsof foveal retinoschisis or earlyonsetmaculardysfunctionhave
to be differentiated. Foveal retinoschisis has rarely been reported as
an apparent autosomal recessive trait in families with predomi-
nantly affected females (Chen et al., 2006; Cibis, 1965; Lewis et al.,
1977; Perez Alvarez and Clement Fernandez, 2002). A male patient
with features of XLRS butwithout a RS1-mutation has been reported
(Hayashi et al., 2004). In Enhanced S-Cone Syndrome (alias
Goldmann-Favre syndrome), which is associated with mutations in
theNR2E3 gene on 15q23 (Haider et al., 2000), a foveal retinoschisis
may be present. The ERG is quite different from the one typical for
XLRS and allows one to distinguish the two disorders (Sohn et al.,
2010). Rare syndromes may present with foveal retinoschisis, they
can be differentiated by presence of other syndrome associated
pathologies (Ayala-Ramirez et al., 2006; Phadke et al., 2011). The
SD-OCT serves to differentiate other causes of early onset macular
dysfunction, e.g. CSNB, cone dysfunction or macular dystrophies.
2.6. Treatment options
In most cases, treatment of XLRS is limited to the prescription of
low-vision aids. Recently, a marked reduction of retinoschisis at the
posterior pole was reported following local application of 2%
dorzolamide (Apushkin and Fishman, 2006; Genead et al., 2010;
Ghajarnia and Gorin, 2007). In about half of the eyes this treatment
is associated with improvement of visual acuity. Not all patients
show a response to this treatment and in some a response is only
seen after several months of application. The response to treatment
is independent of the genotype (Khandhadia et al., 2011; Walia
et al., 2009). When the retinoschisis worsened under therapy,
discontinuation and later retreatment might be beneﬁcial (Thobani
and Fishman, 2010). The value of long-term treatment over many
years still has to be established. At present a treatment trial with
dorzolamide is recommended and should be monitored with visual
acuity and SD-OCT. Long-term application should be based on the
response to treatment in the individual patient.
Pars-plana vitrectomy is indicated in vitreous hemorrhage
without spontaneous resolution to avoid amblyopia or when
retinal detachment occurs (Ferrone et al., 1997; Wu et al., 2007).
Although in a few patients vitreoretinal surgery has been
performed to release vitreoretinal traction (Ikeda et al., 2008; Trese
and Ferrone, 1995), in general prophylactic treatment of reti-
noschisis either by laser or vitreoretinal surgery cannot be recom-
mended due to possible severe long-term complications including
retinal detachment (Kellner et al., 1990; Sobrin et al., 2003).
3. Genetics of XLRS
3.1. Gene identiﬁcation and gene structure
Following the ﬁrst tentative assignment of the RS1 gene to Xg
blood group markers on the short arm of the human X-chromo-
some (Wieacker et al., 1983), a reﬁned mapping of the disease locus
was gradually achieved to an approximately 1000 kb interval on
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1987; Gal et al., 1985; Huopaniemi et al., 1997; Van de Vosse et al.,
1996; Warneke-Wittstock et al., 1998). Within this interval, the RS1
gene was ﬁnally identiﬁed by positional cloning based on retina-
speciﬁc expression of the transcript and segregation analysis of
functional DNA variants with the disease in several large multi-
generation XLRS pedigrees (Sauer et al., 1997).
The RS1 gene spans 32.4 kb of genomic DNA and is organized in
six exons and ﬁve intervening regions. The 3.1 kb mRNA translates
into a precursor protein of 224-amino-acids, termed retinoschisin.
It consists of a 23-amino-acid N-terminal signature characteristic
for cellular proteins processed through the secretory pathway
(Sauer et al., 1997;Wu andMolday, 2003) and a discoidin homology
domain, ﬁrst described in discoidin I from the slime mold Dic-
tyostelium discoideum and since found in many extracellular and
membrane proteins (Poole et al., 1981).
3.2. RS1 expression and its regulation
Across mammalian species, RS1mRNA and protein expression is
speciﬁcally found in the retina (Gehrig et al., 1999b; Molday et al.,
2001; Reid et al., 1999; Sauer et al., 1997) and pineal gland
(Takada et al., 2006), with both organs of a common neuro-
ectodermal origin. In the retina, prominent immunolabeling of
retinoschisin is consistently observed at the extracellular surfaces
of the inner segments of rod and cone photoreceptors, most bipolar
cells as well as the two plexiform layers (Fig. 2) (Grayson et al.,
2000; Molday et al., 2001; Reid et al., 2003; Takada et al., 2004).
In the pineal gland, RS1 expression is conﬁned to pinealocytes and
absent from pineal glia (Takada et al., 2006), the latter ﬁnding
consistent with the ﬁndings in the retina, where retinoschisin is
also absent from homologous Müller glial cells (Grayson et al.,
2000; Molday et al., 2001; Takada et al., 2004).
In postnatal eye development of the mouse, measurable RS1
mRNA expression resumes around P1 reaching adulthood levels
between P5 and P7 which is then maintained throughout adult-
hood (Weber and Kellner, 2007). Comparably, the developing rat
retina reveals weak retinoschisin immuno-labeling at P6 within the
neuroblastic zone while the staining intensity of the outer retina
increases over timewith intense staining of the newly formed inner
segment layer at P10 (Molday et al., 2001). Adult pattern labeling in
the rat is reached around P12. These ﬁndings suggest that across
mammalian species the sustained expression of retinoschisin isFig. 2. Light micrographs of an adult mouse retina immunolabeled for retinoschisin. Left: Dif
the nuclear layers. Right: Immunoﬂuorescence image of the same section showing retinosch
is observed in the inner segment layer with more moderate staining in the outer nuclear, o
segment; ONL, outer nuclear layer, OPL, outer plexiform layer; INL, inner nuclear layer; IPLrequired in adulthood and is likely essential for maintenance of
retinal integrity (Weber et al., 2002).
First insight into RS1 gene regulation was gained from mice
deﬁcient for cone-rod homeobox (CRX) (Livesey et al., 2000) and
neural retina leucine zipper protein (NRL) (Mears et al., 2001),
emphasizing a critical role of these transcription factors for retinal
expression. Another component of a complex regulatory network
of RS1 expression in the retina is the orphan nuclear receptor
NR2E3 (Blackshaw et al., 2001; Corbo et al., 2007; Hsiau et al., 2007;
Livesey et al., 2000; Yoshida et al., 2004). While CRX is a nuclear
protein essential for general photoreceptor maturation for both
rods and cones (Chen et al., 1997; Furukawa et al., 1999), NRL and
NR2E3 have speciﬁc roles in rod photoreceptor maturation and
suppression of cone proliferation (Cheng et al., 2004; Haider et al.,
2001; Mears et al., 2001).
A core proximal promoter encompassing nucleotides 177
toþ32was shown to be sufﬁcient to drive basal RS1 gene activity in
the retina with two evolutionarily conserved CRX binding sites,
CRE1 (26/23) and CRE3 (58/55), stimulating RS1 transcrip-
tion (Langmann et al., 2008). In human, an upstream CpG island
was found to exert strong cis-acting effects on RS1 expression
in vitro and in vivo (Kraus et al., 2011). A second CRX-bound region
strongly conserved between human and mouse was identiﬁed in
the ﬁrst intron of RS1with multiple CRX sites and likely modulates
basal promoter activity (Kraus et al., 2011).
3.3. Spectrum of RS1-associated mutations
To date, a total of 191 unique variants have been reported in the
RS1 gene to be associated with the XLRS phenotype (Leiden Open
Variation Database, LOVD version 2.0, Build 31; http://grenada.
lumc.nl/LOVD2/eye/home.php?select_db¼RS1). Of these, 155
(81%) are nucleotide substitutions resulting in amino acid changes,
alterations of splice site sequences or activation of cryptic splice
sites. In addition, there are 25 (13%) deletions, 5 (3%) duplications, 3
(1.5%) insertions and 3 (1.5%) insertion/deletions. Judging by the
nature of the unique variants, about 40% are expected to represent
true null alleles (i.e. nonsense mutations or frameshift mutations)
and thus should not produce a functional retinoschisin protein.
The most prominent class of unique variants constitute the
missense mutations (100 of 191 unique variants). This type of
mutation affects all regions of the protein although a signiﬁcant
clustering is observed within the discoidin domain (85 of 191). Theferential interference contrast (DIC) image of a mouse retina stained with DAPI to show
isin distribution (green) in the retinal cell layers. Intense immunoﬂurorescence staining
uter plexiform, inner nuclear and inner plexiform layers. OS, outer segment; IS, inner
, inner plexiform layer; GCL, ganglion cell layer. Bar e 20 mm.
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splice site and in-frame deletion mutations) are randomly distrib-
uted along the protein. This suggests that the discoidin domain is
most crucial for RS1 function with strong constraints on deﬁned
amino acid residues.
While XLRS families often segregate unique disease mutations
(e.g. Leu69Pro or Asn104Lys), a number of sequence alterations are
recurrent. Most notably, the missense mutation Glu72Lys has been
reported 66 times while mutations Arg102Trp, Arg102Gln,
Arg141Cys, Pro192Ser, Arg200Cys, and Arg213Trp were found in 17
or more apparently unrelated families, respectively. In addition,
residues such as Glu72, Pro192, Arg197, and Arg209 were found to
be affected by at least 4 different amino acid substitutions. These
commonly altered amino acid residues could be indicative of
mutational hotspots and/or functionally or structurally important
moieties within the mature retinoschisin protein.
4. Mouse models for X-linked juvenile retinoschisis
To date, three independent mouse lines targeting Rs1h, the
murine ortholog of the human RS1 gene (Gehrig et al., 1999b), have
been reported, all resulting in deﬁciency of the endogenous murine
retinoschisin (Jablonski et al., 2005; Weber et al., 2002; Zeng et al.,
2004). Disruption of the Rs1h gene was accomplished by targeting
exon 1 (Zeng et al., 2004) or exon 3 (Weber et al., 2002) with
a neomycin resistance (neor) expression cassette or an in-frame
lacZ-neor expression cassette, respectively. An ENU-induced
mutagenesis resulted in a T > C substitution in intron 2 of the
Rs1h gene at donor splice site position þ2 (Jablonski et al., 2005).
This latter mutation activates an alternative splice donor site 11 bp
further downstream of intron 2 and results in the expression of two
novel retinoschisin isoforms both of which encode a premature
stop codon close to the site of the original mutation.
Predicting a convergent effect of Rs1h targeting on retinoschisin
protein expression in the knockout lines and the splice site muta-
tion, it is not surprising that the retinal phenotypes reveal striking
similarities in the three mouse models (Jablonski et al., 2005;
Weber et al., 2002; Zeng et al., 2004). Prominent morphological
features include disruption of retinal layers accompanied by
displaced photoreceptor nuclei and schisis of the inner nuclear
layer of the retina, as well as disruption of synaptic structures in the
outer plexiform layer (see Fig. 7). OCT has conﬁrmed that micro-
cystic cavities observed using histological techniques are present
in vivo (Xu et al., 2009). These studies further suggest that the
observed cavities are ﬁlled with ﬂuid. Overall, the diseased murine
retina in hemizygous males shows a dramatic and progressive loss
of photoreceptor cells starting at postnatal day 14. Functionally, the
morphological pathology correlates well with an attenuation of the
b-wave in the scotopic ERG response while at the same time the
a-wave appears mostly regular. This electrodiagnostic feature,
known as the ‘negative’ ERG response in human patients (Karpe,
1945; Weleber and Francis, 2006) points to an inner retinal
transmission deﬁcit and, more speciﬁcally, to severe impairment of
bipolar cell-associated pathways. Overall, the structural and
functional changes observed in the retinoschisin-deﬁcient mice
closely mimic human XLRS patients making these mutant mice
excellent models to further study functional aspects of normal and
mutant retinoschisin and to develop potential therapeutic
treatments for XLRS.
5. Structural features of retinoschisin
Retinoschisin, also known as RS1, is a highly conserved 23 kDa
extracellular protein (Sauer et al., 1997). All mammalian proteins for
which the complete sequence is available including human, horse,mouse, rat, bovine, rabbit and canine are 224 amino acids in length
and share 95e97% sequence identity. Orthologs of lower verte-
brates tend to be slightly longer and show a lower degree of
sequence identity. For example, chicken retinoschisin contains 225
amino acids and is 81% identical to human retinoschisin whereas
zebraﬁsh (Danio rerio) and frog (Xenopus laevis) contain 230 and
237 amino acids, respectively, and are about 73% identical.
Retinoschisin is organized in four distinct regions. These include
a 23 amino acid N-terminal leader or signal sequence, a dominant
157 amino acid discoidin domain, a 39 amino acid Rs1 domain
upstream of the discoidin domain, and a 5 amino acid C-terminal
segment (Molday, 2007; Sauer et al., 1997).
5.1. Discoidin (DS) domain
The discoidin (DS) domain, also known as the F5/8 type C
domain, was ﬁrst identiﬁed in the discoidin 1 protein of D. dis-
coideum (Poole et al., 1981). It was subsequently found in a wide
variety of eukaryotic and prokaryotic transmembrane and extra-
cellular proteins either as a single entity or as tandem repeats often
in combination with other extracellular domains (Baumgartner
et al., 1998; Kiedzierska et al., 2007). Some types of proteins
which contain DS domains are blood coagulation factors (Factor V
and Factor VIII), enzymes (galactose oxidase and sialidase), lectins
(discoidin I and II and hemocytin), cell surface tyrosine kinase
receptors (discoidin receptor I and II), and proteins involved in
cellular adhesion, fertilization, migration, signaling, and develop-
ment (SEDI also known as milk fat globule-EGF factor, neurexin IV,
neuropilin, and others).
DS domains are typically composed of approximately 150 amino
acids and share a moderate to high degree of sequence similarity
and protein structural fold. Cysteine residues commonly mark the
beginning and end of the DS domain.
High resolution structures for a number of DS domains have
been determined by X-ray crystallography and nuclear magnetic
resonance (Carafoli et al., 2009; Fuentes-Prior et al., 2002; Lee et al.,
2003; Lin et al., 2007; Macedo-Ribeiro et al., 1999; Pratt et al., 1999;
Vander Kooi et al., 2007). They all have a protein fold similar to that
ﬁrst observed for the crystal structure of the D1 domain of galactose
oxidase (Baumgartner et al., 1998; Ito et al., 1994). The core DS
domain is organized as a compact b sandwich or distorted barrel
consisting of a 5-stranded antiparallel b-sheet (b1, b2, b7, b4, b5)
packed against 3-stranded antiparallel b-sheet (b6, b3, b8) (Fig. 3).
At one end, short segments connect the b-strands and a disulphide
bridge links the N and C-terminal cysteine residues together to
further stabilizing the structure. At the opposite end spikes or loops
extend from the core b-barrel structure. Two or more of these
spikes form a groove or cavity which serves as the recognition site
for interaction of the DS domainwith its ligand. In the case of blood
coagulation Factors V and VIII, the spikes contain a complement of
hydrophobic amino acids which can insert into the plasma
membrane of blood platelets and endothelial cells (Fuentes-Prior
et al., 2002; Macedo-Ribeiro et al., 1999; Pratt et al., 1999). A ring
of charged residues within the hydrophobic groove enables the DS
domains of Factor V and VIII to selectively interact with the polar
head group of phosphatidylserine as a key step in the blood coag-
ulation cascade.
Spike regions and the binding cavity of different DS domains
vary widely in amino acid sequence. This sequence variation
appears to allow DS domains to bind a wide range of ligands
including lipids, carbohydrates and proteins. The DS domain of
SED1 or milk fat globule (MFG), like Factor V and VIII, binds acidic
phospholipids including phosphatidylserine on the membrane
surface of sperm and zona pellucida as an essential step in fertil-
ization (Ensslin and Shur, 2003; Raymond et al., 2009). Discoidin
Fig. 3. Sequence alignment and structural homology model of retinoschisin discoidin domain. (a) Alignment of the discoidin domain sequences of human (Hu-RS1) and mouse (Mo-
RS1) retinoschisin with D2 discoidin domain sequences of human Factor V (Hu-FV) and human Factor VIII (Hu-FVIII). Numbering is for retinoschisin; yellow shows amino acid
identity; b-strands and spike regions are shown below sequences; cysteine residues involved in disulphide bonds are outlined. (b) Homology model of the discoidin domain of
retinoschisin obtained using Factor V as a template. Cysteine residues including those involved in intramolecular disulphide bonds are shown in blue. Modiﬁed fromWu and Molday
(2003).
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receptors. The extracellular DS domains of these receptors bind
collagen and initiate receptor phosphorylation which in turn
regulates a variety of cellular processes including cell proliferation,
adhesion and migration (Carafoli et al., 2009; Vogel et al., 1997,
2006). Neuropilin, a cell surface receptor which regulates a variety
of developmental processes including cell adhesion, angiogenesis,
and neuronal migration binds semaphorin and VEGF (Gu et al.,
2003; Vander Kooi et al., 2007). Finally, DS domains of some lec-
tins, sialidases and chitobiases bind various glycoconjugates
(Baumgartner et al., 1998; Mathieu et al., 2010). The ligands for
most DS domains, however, have yet to be determined. In contrast
to the spike regions, the amino acid sequence of the core b-barrel
structure of the DS domain is more highly conserved consistent
with its role as a scaffold for the hypervariable spikes (Fig. 3a).A high resolution structure of the retinoschisin DS domain has
yet to be determined. However, homology models have been
generated using the C2 discoidin domains of Factor V (39%
sequence identity) and Factor VIII (33% sequence identity) as
templates (Fraternali et al., 2003; Sergeev et al., 2010; Wu and
Molday, 2003). In these models the DS domain of retinoschisin is
predicted to have a core hydrophobic distorted b-barrel structure
consisting of 8 b-strands (Fig. 3b). Three prominent spikes protrude
from one end of the core structure with a shorter hairpin loop
between b-strands 5 and 6 (Wu and Molday, 2003). There are 5
cysteine residues within the DS domain (Fig. 3a). The conserved
cysteine residues at the beginning (C63) and end (C219) are
modeled with a disulphide bridge as has been found for
corresponding cysteine residues in other eukaryotic DS domains
(Carafoli et al., 2009; Lee et al., 2003; Macedo-Ribeiro et al., 1999).
Fig. 4. Oligomeric structure of retinoschisin. (a) SDS gels of wild-type (WT) and
mutant retinoschisin proteins run under nonreducing conditions. WT and C40S mutant
run as a 186 kDa octamer; C59S/C223S mutant runs as a dimer; and C40S/C59S/C223S
runs as a monomer. (b) Working model for the organization of retinoschisin subunits
into an octameric complex via disulphide bonding. The octameric structure is main-
tained by C59eC223 disulphide bonds. Within the octamer, four dimers are main-
tained by disulphide bonding involving C40. Rs1 domain and discoidin domain (DS)
and carboxyl terminal segment (Ct) are indicated. Modiﬁed from Wu et al. (2005).
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in spike 3 (C142), are in close proximity to each other and have been
modeled to join through a disulphide bridge. Mass spectrometric
analyses of tryptic peptides from nonreduced retinoschisin
together with mutagenesis studies support the existence of a C110-
C142 disulphide bond (Wu and Molday, 2003; Wu et al., 2005). The
C63-C219 and C110-C142 intramolecular disulphide bonds are
crucial for the proper folding and stability of retinoschisin since
substitution of any of these residues with a serine results in a mis-
folded protein which is retained in the cell by the quality control
system of the ER (Wu and Molday, 2003). Furthermore, genetic
screening has revealed that missense mutations involving cysteine
residues at positions 110, 142, or 219 (C110Y, C142W, C219 R/G) are
responsible for XLRS (Hiriyanna et al., 1999). A missense mutation
in C63 is also likely to cause XLRS although to date patients with
such a mutation have not been reported.
An additional cysteine residue is present at position 83 within
the retinoschisin DS domain. The corresponding position is
occupied by alanine in the DS domain of Factor V and VIII and most
other DS containing proteins. Mass spectrometry of nonreduced
bovine retinoschisin treated with N-ethylmaleimide prior to
protease digestion together with cysteine mutagenesis studies
support the view that C83 is buried within the core DS structure in
its reduced state (Wu et al., 2005).
5.2. Rs1 domain and the C-terminal segment
The region upstream of the DS domain lacks signiﬁcant
sequence similarity to other proteins in the databases and hence
has been called the Rs1 domain (Molday, 2007). It contains four
conserved cysteine residues, three of which (C38, C40, C42) are
within a conserved KACKCDCQ motif. A fourth cysteine Cys59 is
located just prior to the start of the DS domain. A stretch of 5 highly
conserved amino acids lies just downstream of the DS domain at
the carboxyl terminal end of retinoschisin. This segment contains
a conserved cysteine (C223) at the penultimate position of reti-
noschisin which is preceded by a conserved lysine residue.
TheRS1 domain andC-terminal segment playa crucial role in the
oligomerization state of retinoschisin (Fig. 4). Site directed muta-
genesis studies have implicated C59 and C223 in the formation of
intermolecular disulphide bridges between adjacent retinoschisin
subunits (Wu and Molday, 2003; Wu et al., 2005). These disulphide
bonds are required for homo-octameric complex formation since
elimination of these linkages through serine substitutions abolishes
the complexevenunder nondenaturing conditions (Wuet al., 2005).
The C40 residue participates in an additional intermolecular disul-
phide bridge that links two retinoschisin subunits together as
dimers within the octameric complex (see below). The role of C38
and C42 and their possible involvement in disulphide bonding
remains to be determined experimentally.
5.3. Leader or signal sequence
Most proteins which are destined to be secreted from cells
contain a short N-terminal sequence known as a leader or signal
sequence or peptide (Blobel and Dobberstein, 1975; Gierasch, 1989;
Martoglio and Dobberstein, 1998; Walter and Johnson, 1994). The
signal sequence is synthesized off of free ribosomes. As the signal
sequence emerges from the ribosome, it interacts with the signal
recognition particle (SRP) which in turn directs the complex to the
cytoplasmic surface of the endoplasmic reticulum (ER) through its
interaction with the SRP receptor. The nascent polypeptide is then
transported across the ER membrane through a channel complex
known as the peptide translocation complex or translocon. As the
peptide emerges from the translocon, the signal peptide is cleavedby a signal peptidase present on the lumen side of the ER
membrane and the nascent polypeptide chain undergoes cotrans-
lational processing and folding into a native-like conformation
(Fig. 5a). In some cases it can subsequently undergoes subunit
assembly before emerging from the ER into transport vesicles. After
further processing in the Golgi network, the post-Golgi transport
vesicles fuse with the plasma membrane and release the protein
into the extracellular environment.
A signal sequencehas three characteristic features (Martoglio and
Dobberstein, 1998). It has an N-terminal stretch of polar residues
with a net positive charge, a central core hydrophobic segment of
6e15aminoacids, andadownstreamsegmentofpolar residuesoften
containing glycine or proline residues and small uncharged polar
residues at positions 3 and1 from the site of cleavage.
When retinoschisin was ﬁrst cloned in 1997 (Sauer et al., 1997),
the N-terminal 23 amino acid was found to have the structural
features of a cleavable signal sequence. N-terminal sequencing of
puriﬁed bovine retinoschisin by Edman degradation and tryptic
peptide analysis by mass spectrometry have conﬁrmed that
cleavage does occur following serine at position 23 to generate
a 201 amino acid mature protein (Wu et al., 2005). Subsequent
studies of mouse retinoschisin, however, have revealed the
existence of another signal peptidase cleavage site at position 21
(Vijayasarathy et al., 2006). The physiological signiﬁcance of the
two mature isoforms of retinoschisin has not been established.5.4. Oligomeric structure of retinoschisin
Although retinoschisin is synthesized as aw23 kDa protein, it is
assembled in the ER and secreted from cells as complex composed
of four disulphide dimers within a disulphide-linked homo-octa-
meric complex (Fig. 4). Evidence for this complex has come from
biochemical analysis of retinal membrane extracts and cellular and
secreted fractions of cultured Weri retinoblastoma cells and
HEK293 cells expressing wild-type (WT) and mutant retinoschisin
(Molday et al., 2001; Wu et al., 2005). Under disulphide reducing
Fig. 5. Diagram depicting the effect of various disease-causing missense mutations on retinoschisin synthesis, protein folding/ER retention, and subunit oligomerization. (a) Wild-
type retinoschisin synthesized off of ribosomes associated with the ER membrane is threaded through the translocon and the signal sequence is cleaved by a signal peptidase in the
ER lumen to produce the mature folded retinoschisin (RS1) polypeptide. RS1 assembles into a disulphide-linked octameric complex which is exported from cells via the secretory
pathway (not shown). (b) Mutations in the signal sequence (L12H and L13P) prevent the insertion of the nascent polypeptide chain into the translocon of the ER resulting in
a misfolded polypeptide localized to the cytoplasm where it is rapid degraded by the proteosome. Mutations in the discoidin (DS) domain enable the nascent polypeptide chain to
be transported into the ER lumen, but the protein fails to fold into a native conformation and as a result is retained in the ER. Cysteine mutations (C59S and C223R) in the regions
ﬂanking the DS domain result in relatively normal protein synthesis, folding, and disulphide-linked dimerization, but fail to further oligomerize into an octameric complex. As
a result the retinoschisin dimers are secreted from cells, but are non-functional due to their failure to form disulphide-linked octamers.
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polyacrylamide gels as a 23 kDa protein in agreement with its size
predicted from its amino acid sequence. In contrast, under nonre-
ducing conditions retinoschisin and the C40S mutant run as
a 186 kDa complex (Fig. 4a). The retinoschisin C38S/C40S/C42S
triple mutant also runs predominantly as a 186 kDa complex under
nonreducing conditions, but in addition the monomer and inter-
mediate oligomers corresponding to the dimer through heptamer
are visible providing strong evidence that the 186 kDa protein
consists of 8 subunits (Wu et al., 2005).
Cysteine residues which form intermolecular disulphide bonds
responsible for the homo-octameric structure were ﬁrst identiﬁed
by site-directed mutagenesis (Wu and Molday, 2003; Wu et al.,
2005). Substitution of the cysteine at position 59 in the RS1
domain and/or the cysteine at position 223 in the C-terminal
segment with serine prevents the formation of the 186 kDa octa-
meric complex (Fig. 4a). Instead, these mutants migrate as dimers
indicating that one or more additional disulphide bridge involving
different cysteine residues are responsible for dimer formation.
Cysteine at position 40 in the RS1 domain has been implicated in
dimer formation since the C59S/C223S/C40S triplemutantmigrates
as a monomer under both reducing and nonreducing conditions.
A working model which encompasses these observations is
illustrated in Fig. 4b.
Disulphide-linked homo-octamerization appears to play an
essential role in the function of retinoschisin as an extracellular
protein since mutations which disrupt the complex i.e. C59S and
C223R, are known to cause XLRS. The oligomeric nature may be
important in increasing the binding afﬁnity of retinoschisin for its
receptor on cell surfaces. This is supported in studies which have
shown that wild-type homo-octameric retinoschisin efﬁciently
binds to galactose-agarose whereas the dimeric mutant (C59S/C223S) exhibits weak binding. Most DS domain containing proteins
have either multiple DS domains within the polypeptide chain or
assemble as oligomers suggesting that multiple DS domains are
needed to enhance binding to their ligands.
6. Binding of retinoschisin to photoreceptor and bipolar cell
surfaces
Retinoschisin expressed and secreted primarily from photore-
ceptor and to a lesser extent bipolar cells bind strongly and
speciﬁcally to the surface of these cells as revealed by immunocy-
tochemical and biochemical studies (Molday et al., 2001; Reid et al.,
2003; Takada et al., 2004). In order to gain insight into the function
of retinoschisin in the retina, a number of studies have been
directed toward identifying the molecular component(s) which
anchor retinoschisin to the surface of photoreceptor and bipolar
cells through its DS domain. Three candidates have emerged from
these studies.
6.1. Na/K ATPase-SARM1 complex
Na/K ATPase is a P-type ATPase which plays an essential role in
generating Na and K gradients across the plasma membrane
(Blanco and Mercer, 1998; Jorgensen et al., 2003; Kaplan, 2002). It
consists of two principal subunits, a or A subunit of 112 kDa and
b or B subunit of 40e60 kDa. An additional FXYD protein of
approximately 10 kDa is present in some tissue speciﬁc Na/K
ATPases. There are four isoforms of the a catalytic subunit (a1ea4)
encoded by the ATP1A1-4 genes and four b-isoforms (b1eb4)
encoded by the ATP1B1-4 genes. The a subunit consists of 10
membrane spanning segments with the N and C termini and the
large catalytic domain located on the cytoplasmic side of the
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segments on the extracellular side of the membrane. The b subunit
contains a single transmembrane segment and a relatively large,
highly glycosylated extracellular domain. This subunit plays
a crucial role in the proper folding and cellular trafﬁcking of Na/K
ATPase and is required for generating a functional protein complex.
Earlier studies directed toward mapping the various Na/K ATPase
isoforms in the mouse retina showed that Na/K ATPase (a3/b2) is
amajor isoform in the retina and is restricted to photoreceptors and
bipolar cells (Wetzel et al., 1999). The b2 subunit of Na/K ATPases in
neuronal cells has been identiﬁed as the AMOG (AdhesionMolecule
On Glia) protein implicated in neuraleglia interactions (Antonicek
et al., 1987; Gloor et al., 1990; Magyar et al., 1994; Mink et al.,
2001; Molthagen et al., 1996). Hence, this subunit not only
functions as an accessory subunit for the catalytic subunit of Na/K
ATPase, but is also involved in cell adhesion.
SARM1, the sterile alpha and TIR motif-containing 1 protein, is
an intracellular protein that plays a role in innate immunity as
a negative regulator of Toll-like receptor 3 (TLR3) (Carty et al., 2006;
Chen et al., 2011; Mink et al., 2001; O’Neill and Bowie, 2007). It has
also been implicated in the regulation of neuronal cell morphology
through its interaction with syndecan-2 (Chen et al., 2011).
When a detergent solubilized retina extract was applied to
a solid support consisting of a highly speciﬁc retinoschisin mono-
clonal antibody coupled to Sepharose, the a3 and b2 subunits of Na/
K ATPase, and SARM1, were found to be major components which
co-immunoprecipitated with retinoschisin as revealed by both
mass spectrometry and western blotting (Molday et al., 2007).
Immunoﬂuorescence labeling studies conﬁrmed the colocalization
of retinoschisin and Na/K ATPase (a3, b2) to photoreceptor and
bipolar cells in the mouse retina. Immunoﬂuorescence microscopy
also indicated that SARM1 was present in photoreceptors and
bipolar cells.
Friedrich et al. (2011) have subsequently used knockoutmice and
heterologous protein expression in HEK293 cells to study the inter-
actionof retinoschisinwithNa/KATPase. Both retinoschisin andNa/K
ATPase expressionwere severely reduced in the retinas of Atp1b2/
mice deﬁcient in b2 subunit of Na/K ATPase (Magyar et al., 1994).
Exogenously added retinoschisin bound to retinal membranes of
retinoschisin-deﬁcient Rs1h/Y/Atp1b2þ/ mice which express the
Na/K ATPase (a3/b2) isoform, but failed to bind membranes from
Rs1h/Y/Atp1b2/ mice deﬁcient in the b2 isoform (Friedrich et al.,
2011). Furthermore, retinoschisin was found to speciﬁcally bind to
membrane extracts from HEK293 cells co-expressing the a3 and b2
subunits of Na/K ATPase, but not membranes from nontransfected
cells or cells expressing only one of the subunits.
Taken together, these studies provide strong support for the role
of Na/K ATPase in anchoring retinoschisin to the surface
membranes of photoreceptors and bipolar cells. The site of inter-
action of retinoschisinwith Na/K ATPase remains to be determined.
However, based on structure-function analysis of Na/K ATPase and
studies showing that the b2 subunit (AMOG) is involved in
neuraleglial interactions in neural tissue (Gloor et al., 1990), the
extracellular domain of b2 subunit of the Na/K ATPase complex
most likely contains the binding site for retinoschisin (Friedrich
et al., 2011; Molday et al., 2007). Previous studies have shown
that retinoschisin binds to modiﬁed galactose residues, a property
that can be used to purify retinoschisin (Dyka et al., 2008). Hence, it
is possible that the site of interaction could be one ormore of the N-
glycans of the b2 subunit. Alternatively the polypeptide chain of the
b2 subunit may contain the binding site.
Since SARM1 co-immunoprecipitates and co-localizes with
retinoschisin and the Na/K ATPase in retina, SARM1 has been
suggested to be a component of the retinoschisin-Na/K ATPase
complex (Molday et al., 2007). However, it remains to bedetermined whether SARM1 acts as a signaling molecule to
modulate photoreceptor and bipolar cell homeostasis or is only
a passive member of the complex. Analysis of the retina of a SARM1
knockout mouse would provide insight into the possible role of
SARM1 in retinal structure and function.
6.2. Phosphatidylserine (PS)
Phosphatidylserine (PS) is an acidic phospholipid principally
localized to the cytoplasmic leaﬂet of cell membranes and in
particular the plasma membrane. In some instances, the asym-
metrical distribution of PS is compromised through cell injury
leading to the exposure of PS on the outer leaﬂet of cells. This can
trigger such cellular events as phagocytosis or protein binding.
A number of discoidin-domain containing proteins have been
shown to bind PS, with blood coagulation Factor V and Factor VIII
being the most-well studied (Ortel et al., 1992a, 1992b; Zwaal et al.,
1998). In resting platelets and endothelial cells, PS is found exclu-
sively on the inner leaﬂet of the cell surfacemembrane. Upon injury
to blood vessels a series of reactions occurs that leads to the loss in
PS membrane asymmetry as part of the platelet/endothelial acti-
vation process. This allows Factor V and Factor VIII to bind to PS on
the surface of the activated cells through their DS domains and
initiate the blood coagulation cascade (Fuentes-Prior et al., 2002).
Sequence similarity between retinoschisin and Factor V together
with early homology modeling and molecular dynamics ﬁrst led to
the suggestion that PS may serve as the ligand for retinoschisin
(Fraternali et al., 2003). Sieving and colleagues have pursued this
idea experimentally showing that a bacterial expressed recombi-
nant protein corresponding to the DS domain of retinoschisin
bound to immobilized acidic phospholipids and in particular PS
(Vijayasarathy et al., 2007). They subsequently showed that reti-
noschisin interacts with PS containing planar lipid bilayers in the
presence of Ca2þ as revealed by atomic force microscopy (Kotova
et al., 2010). These studies used lipid mixtures containing varying
amounts of PS down to a molar composition of 12%, a concentrate
which resembles the PS composition of synaptic vesicles. However,
since the external surface of most cells typically contains extremely
low levels of PS due to PS asymmetry generated by amino-
phospholipid ﬂippases (Folmer et al., 2009), the physiological
signiﬁcance of the interaction of retinoschisin to these model
membranes is unclear and needs further clariﬁcation.
Two independent groups have investigated the binding of reti-
noschisin to PS-containing lipid vesicles derived from a mixture of
synthetic phospholipids or retinal lipids (Friedrich et al., 2011;
Molday et al., 2007). In both studies, retinoschisin failed to bind
these PS containing membranes even in the presence of Ca2þ.
Hence, it remains to be determined if PS mediates the speciﬁc
binding of retinoschisin to photoreceptor and bipolar cell surfaces
or alternatively adsorbs to negatively charged lipid surfaces under
certain conditions through weak ionic interactions.
6.3. L-type voltage-gated calcium channels
L-type voltage-gated calcium channels play a crucial role in
a number of cellular process including muscle contraction, cell
motility, cell division and synaptic transmission (Hosey et al., 1996).
They consist of 4 subunits, a1, b, a2 and d, with a1 being responsible
for most of the electrophysiological and pharmacological proper-
ties of the channel and the other accessory subunits being impor-
tant for channel stability andmodulation of the gating and kinetics.
L-type voltage-gated channels play a crucial role in photoreceptor-
bipolar neurotransmission. In mammalian retina, rod and cone
photoreceptors express the CACNA1F (a1F) subunit encoded by the
CACNA1F gene (Morgans, 2001; Morgans et al., 2005). In addition,
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tions in the CACNA1F are known to cause incomplete congenital
stationary night blindness (CSNB2) associated with a loss in b-wave
amplitude of the ERGs (Bech-Hansen et al., 1998; Shi et al., 2009;
Strom et al., 1998).
Shi et al. (2009) have recently examined the interaction of ret-
inoschisin with L-type voltage-gated calcium channels from chick
retina. In these studies, an anti-retinoschisin antibody was found to
co-immunoprecipitate an L-type voltage-gated channel with reti-
noschisin. Using a mammalian two-hybrid assay, they further
showed that retinoschisin binds within a 500 amino acid
N-terminal region of chicken CACNA1D gene, which is highly
conserved in human CACNA1D and CACNA1F subunits (Shi et al.,
2009). On the basis of these studies, they have suggested that ret-
inoschisin plays an important role in the retention of L-type voltage
calcium channels in photoreceptor presynaptic membranes and is
indirectly involved in photoreceptor-bipolar transmission. The
possible interaction of retinoschisin with these channels is
intriguing since it may explain the loss in ERG b-wave amplitude
which is observed in patients with XLRS and CSNB2. However, the
distribution of the retinoschisin and L-type channels differ signif-
icantly in the retina. Whereas retinoschisin is widely distributed in
photoreceptor and bipolar cells as previously discussed, the CAC-
NA1D and CNCNA1F channels are restricted to the outer and inner
plexiform layers (Morgans, 2001; Morgans et al., 2005). Hence, if
the interaction of retinoschisin with these channels can be
conﬁrmed by additional studies, it would suggest that retinoschisin
likely has multiple membrane binding partners.
7. Possible function of retinoschisin in the retina
The function of retinoschisin in the retina is not well under-
stood. However, it has been generally suggested that retinoschisin
functions as a cell adhesion protein to maintain the cellular orga-
nization of the retina and the structural integrity of the
photoreceptor-bipolar synapse. This is based on the ﬁnding that
XLRS patients and Rs1h knockout mice exhibit a highly disorga-
nized retinal architecture and the existence of the DS domainwhich
has been implicated in cell adhesion processes. However, to date
there is no direct evidence that retinoschisin interacts with other
components of the extracellular matrix or participates in direct
cellecell interactions to stabilize the structure of the retina.
Another possible role of retinoschisin may be to help regulate
the ﬂuid balance between the intracellular and extracellular envi-
ronment particularly within the photoreceptor and bipolar cell
layers. Regulation of cell volume and tissue osmotic homeostasis is
a complex process involving numerous membrane transporters
and channels including the NaK ATPase. One can speculate that the
binding of retinoschisin to the NaK ATPase may directly affect the
activity of this pump in controlling ion gradients and consequently
ﬂuid balance and tissue osmolarity. Alternatively, the binding of
retinoschisin to the NaK ATPase may inﬂuence ﬂuid balance indi-
rectly through an intracellular signaling pathway. In such a case
loss of functional retinoschisin could cause ﬂuid accumulation in
the extracellular environment in the form of ﬂuid-ﬁlled cystic
cavity as observed in the retina of XLRS patients and Rs1h knockout
mice by OCT and histology (Eriksson et al., 2004; Renner et al.,
2008; Weber et al., 2002; Xu et al., 2009). The cystic cavities
could in turn disrupt the organized layers of the retina causing
a dysfunction of the photoreceptor-bipolar synapse. Indeed, this
may also explain the effect of dorzolamide, a carbonic anhydrase
inhibitor, in reducing schisis cavities in some XLRS patients as
observed by OCT (Apushkin and Fishman, 2006). It alsomay explain
why retina splitting and cystic cavities are sometimes seen in layers
of the retinawhich are removed from cells expressing retinoschisin.Additional studies are needed to test this model and further deﬁne
the role of retinoschisin in retinal cell physiology.
8. Molecular and cellular mechanisms underlying XLRS
As discussed above, up to 40% of the disease-causing mutations
are nonsense or frameshift mutations which are predicted to result
in the absence of a full-length retinoschisin protein. Any residual
translationwould likely result in an unstable truncated polypeptide
that would be rapidly degraded in the cell. Hence, the disease
phenotype for such mutations is expected to arise from a complete
deﬁciency of retinoschisin. Over 50% of disease-causing mutations,
however, are missense mutations which allow the translation of
the full-length mutant protein. A number of studies have been
directed toward determining how various disease-associated
missense mutations affect retinoschisin expression, subcellular
localization, and protein structure (Vijayasarathy et al., 2010; Wang
et al., 2002; Wu and Molday, 2003). Three principal mechanisms
have been deﬁned all of which produce a non-functional protein
(Fig. 5). This is generally consistent with studies that have found
little or no signiﬁcant correlation between genotype and pheno-
type in XLRS patients (Eksandh et al., 2000; Sergeev et al., 2010;
Shinoda et al., 2000).
8.1. Mutations in the DS domain cause protein misfolding and
retention in the ER
A number of studies have been carried out to assess the effects of
RS1 disease-linked missense mutations in the DS domain on reti-
noschisin structure and function (Curat et al., 2001; Iannaccone et al.,
2006; Sergeev et al., 2010; Vijayasarathy et al., 2010; Walia et al.,
2009; Wang et al., 2002; Wu and Molday, 2003). In one study,
Curat et al. (2001) analyzedmutations G70S, R102W,W112C, G140R,
G178D, P193L, P203L, R213Wand E215Q at homologous positions of
the human discoidin receptor 1 (DDR1). In this chimeric receptor
system, some residues affected receptor phosphorylation, while
others inﬂuenced both collagen-binding and receptor activation.
In another experimental approach, Wang et al. (2002) and Wu
and Molday (2003) expressed wild-type and mutant retinoschisin
in culture cells and compared their expression, biochemical prop-
erties, and secretion from cells. Whereas the wild-type protein was
efﬁciently expressed and secreted from cells, the majority of the
proteins with disease-associated mutations in the DS domain (e.g.
G70S, E72K, R102W, G109R, G109E, C110Y, W112C, R141C, C142W,
D143V, R182C, P203L, R213W, C219R) were severely misfolding and
retained in the endoplasmic reticulum (ER) by the quality control
system of cells (Ellgaard et al., 1999). Mutations which result in
either the additionor removal of cysteine residues inparticularwere
found to induce the formation of aberrant disulphide bridges
leading to signiﬁcantprotein aggregationwithin theERof thecells as
analyzed on nonreducing SDS polyacrylamide gels (Wu andMolday,
2003). Disease-causing mutations in the core barrel structure and
spike regions which do not involve cysteine residues also caused
protein misfolding most likely by interfering with speciﬁc hydro-
phobic, hydrogen bonding, and/or electrostatic interactions essen-
tial for proper protein folding. The large number of disease-
associated missense mutations in the retinoschisin DS domain
which result in protein misfolding and ER retention indicates that
this domain is a ﬁnely tuned structure that cannot accommodate
many amino acid substitutions (Fig. 6). The ﬁnding that these
mutants are expressed but not secreted from cells suggests that the
disease phenotype arises primarily from the loss in functional
protein. Any stress resulting from the unfolded protein response
(Nakatsukasa and Brodsky, 2008) appears to have little if any
inﬂuence on the disease phenotype (Vijayasarathy et al., 2010).
Fig. 6. Location of selected missense mutations within retinoschisin structure. (a) A
linear diagram showing the organization of retinoschisin into it various domains along
with selected disease-associated missense mutations (SS e cleavable signal sequence;
Rs1 domain; discoidin domain; and Ct e C-terminal segment). (b) Selected missense
mutations are shown within a model of the mature retinoschisin subunit. The struc-
ture of the Rs1 domain and C-terminal segment is not known and drawn as lines
within a dashed ellipse with mutations shown in green spheres. The discoidin domain
structure is based on the homology modeling shown in Fig. 3b with mutations shown
in blue spheres with the exception of R141H which is shown as a red sphere.
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To date two disease-linked missense mutations (C59S and
C223R) have been found in the regions ﬂanking the DS domain
(Gehrig et al., 1999a; Hiriyanna et al., 1999). Neither mutation
signiﬁcantly interferes with protein folding and secretion from
cells. Instead, they prevent the assembly of retinoschisin into
a homo-octameric complex (Fig. 5b) (Wu and Molday, 2003). These
studies highlight the importance of the octameric structure in the
function of retinoschisin as an extracellular protein. Disease-
causing missense mutations in other residues of the RS1 domain
and C-terminal segment have yet to be found.
8.3. Mutations in the signal sequence cause abnormal protein
synthesis and localization
Disease-causing missense mutations in the 23-amino-acid
signal sequence of RS1 (L12H, L13P) cause severely reduced protein
expression and mislocalization within cells (Hiriyanna et al., 1999;Vijayasarathy et al., 2010;Wang et al., 2002;Wu andMolday, 2003).
These mutations most likely disrupt the a-helical conformation of
the leader sequence thereby preventing the nascent polypeptide
chain from inserting into the ER membrane during protein
biosynthesis (Fig. 5b). As a result the protein is mislocalized to the
cytoplasm where it is rapidly degraded by the proteasomal degra-
dation pathway (Wang et al., 2002; Wu and Molday, 2003).8.4. Other pathogenic mechanisms
Although most disease-associated missense mutations fall into
one of the three mechanisms discussed above and illustrated in
Fig. 5, at least one disease-associated mutation may cause XLRS by
a differentmechanism. The R141Hmutant is secreted from cultured
cells as a disulphide associated octamer and exhibits similar
galactose binding properties as wild-type retinoschisin (Dyka and
Molday, 2007; Dyka et al., 2008; Wang et al., 2006). The R141H
mutation located in spike 3 of the DS domain (Fig. 6b) appears to
enable retinoschisin to fold and assemble into a native-like octa-
meric complex which is secreted from cells, but this substitution
may interfere with the ability of retinoschisin to bind to its cognate
receptor on retinal cell surfaces. Alternatively, this mutant may
bind to its receptor, but serve as an antagonist with respect to
retinoschisin function. Finally, it is possible that retinal cells differ
sufﬁciently from culture cells in their chaperones and ER quality
control system such that the R141H mutant is retained in retinal
cells, but not in culture cells. Indeed, differential effects of some
mutations on the folding and secretion of proteins have been
observed in different cell types. For example, a small amount of the
R141Gmutant has been found to be secreted from transfected COS-
7 cells, whereas secretion of this mutant was not detected in
transfected HEK293 cells (Dyka and Molday, 2007; Wang et al.,
2002). Wang et al. (2006) have also reported that small amounts
of several other disease-associated mutants (F108C, R182C, H207Q
and R209H, and C219G) are secreted from COS-7 cells, but it is
unclear whether such mutants are functionally active.9. Gene therapy in mouse models of XLRS
Gene therapy is a viable approach to prevent or slow vision loss
in inherited retinal degenerative diseases (Dinculescu et al., 2005;
Liu et al., 2010; Smith et al., 2009). For retinal degeneration caused
by complete or partial loss in protein function, the delivery of the
normal gene to cells harboring the defective gene is often sufﬁcient
to restore protein function and halt or at least slow retinal degen-
eration. Most studies have employed recombinant adeno-
associated viral (rAAV) vectors to deliver the gene of interest to
photoreceptor or RPE cells (Liu et al., 2010; Smith et al., 2009).
These vectors have a number of advantages. They are nontoxic and
nonimmunogenic when administered by subretinal injections,
come in a variety of serotypes which differ in speciﬁc cell trans-
fection efﬁciencies, effectively transduce nondividing cells
including photoreceptors and RPE cells, and display long-term gene
expression. Gene replacement strategy has proven successful in
animal models for a number of recessive retinal degenerative
diseases caused bymutations in genes expressed in retinal pigment
epithelial cells (RPE) or photoreceptors (Acland et al., 2001;
Alexander et al., 2007; Boye et al., 2010, 2011; Kong et al., 2008; Min
et al., 2005; Pawlyk et al., 2005). Recently, Phase I/II clinical trials
have shown that AAV-mediated gene therapy is safe and can
restore some vision in individuals with autosomal recessive Leber
congenital amaurosis type 2 (LCA2) associated with mutations in
RPE65 (Bainbridge et al., 2008; Cideciyan et al., 2008; Jacobson
et al., 2011; Maguire et al., 2009, 2008).
Fig. 7. Retinoschisin expression and retinal structure in a Rs1h knockout mouse treated with rAAV containing the human RS1 cDNA under control of an upstream mouse opsin
promoter (rAAV-mOps-RS1). The right eye of a 14 day old Rs1h knockout mouse was injected subretinally with rAAV-mOps-RS1 (Treated); the left eye was not injected and served as
a contra lateral control (Untreated). One year post-treatment, the mouse was sacriﬁced and the both the untreated and treated retinas were immunolabeled for retinoschisin and
visualized by confocal scanning microscopy. The untreated eye showing no retinoschisin expression was highly disorganized with a merging of the inner and outer nuclear layers
and disrupted outer plexiform layer. The treated eye showed retinoschisin expression and distribution comparable to that of a wild-type retina (see Fig. 2) and signiﬁcant
improvement in retinal structure and photoreceptor survival as determined by the thickness of the outer nuclear layer (ONL). Bar e 20 mm.
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noschisin function, gene replacement therapy has been considered
as a potential treatment for this disease. Furthermore, since reti-
noschisin functions as an extracellular protein, beneﬁcial treatment
is not necessarily restricted to the transfected cell expressing the
replacement gene, but can encompass a wider area due to the
spread of the secreted protein from the site of expression. Two
independent groups have investigated the potential of gene
replacement therapy to restore retinal structure and function and
slow retinal degeneration in Rs1h knockout mice as an animal
model for XLRS (Janssen et al., 2008; Kjellstrom et al., 2007; Park
et al., 2009; Min et al., 2005; Takada et al., 2008; Zeng et al., 2004).
In one study, the normal recombinant AAV serotype 5 contain-
ing the human RS1 cDNA under the control of the mouse
photoreceptor-speciﬁc mouse opsin promoter (AAV5-mOPs-RS1)
was injected into the subretinal space of the right eyes of 14-day old
Rs1h knockout mice with the untreated left eyes serving as controls
(Janssen et al., 2008; Min et al., 2005). A gradual increase in reti-
noschisin expression was observed by immunoﬂuorescence
microscopy over the initial 12 week post-injection period. After this
initial period, immunostaining of retinoschisin was seen
throughout most of the treated retina with a distribution similar to
that observed for wild-typemice. In particular, intense staining was
observed in the inner segment layer andmore moderate staining in
the outer nuclear layer (ONL) and outer plexiform layer (OPL) of the
outer retina and inner nuclear layer (INL) and inner plexiform layer
(IPL) of the inner retina (Fig. 7). Retinoschisin was absent in the
untreated control retina of the Rsh1 knockout mouse as expected.
Although RS1 gene expressionwas restricted to photoreceptors due
to the mouse opsin promoter, the presence of retinoschisin in other
layers of the retina indicated that the secreted protein was able to
spread to other parts of the retina.
Retinoschisin expression in the treated eyes of Rsh1 mice coin-
cided with a signiﬁcant improvement in the structure and function
of the retina (Janssen et al., 2008; Min et al., 2005). The treated
retina showed well-organized retina layers, the absence of cystic
cavities within the bipolar cell layer, preservation of scotopic and
photopic ERGs, and stabilization of the ONL thickness characteristic
of sustained photoreceptor cell survival (Fig. 7). The untreated
retina on the other hand showed the characteristic features of the
advanced disease including disorganization of the retinal layers,loss in scotopic and photopic ERS response, and progressive
degeneration of rod and cone photoreceptor cells. Importantly,
retinoschisin expression and distribution together with improved
structure and function of the retina following a single subretinal
injection persisted for the lifetime of the mouse, i.e. >19 months
(unpublished results). However, rescue of retina structure and
function was dependent on the age at which the mice were treated
with older mice showing signiﬁcantly reduced therapeutic beneﬁt
(Janssen et al., 2008).
Sieving and coworkers have achieved similar rescue of retinal
structure and function in Rsh1 knockout mice using a different
although related approach (Kjellstrom et al., 2007; Takada et al.,
2008; Zeng et al., 2004) In their studies, rAAV2 containing the
mouse Rs1h cDNA under the control of the general CMV promoter
was administered to knockout mice of various ages by intravitreal
injections. Signiﬁcant improvement in ERGs, retinal structure and
photoreceptor cell survival was observed with the most evident
success achieved when injections were carried out on 14 day old
mice. Retinoschisin expression together with improved retinal
structure and function persisted for over 15 months. Detailed
structural analysis also showed an improved OPL structure which
correlated with enhanced ERGs. Although the inner limiting
membrane of wild-type mice appears to limit penetration of rAAV2
into the retina by intravitreal injections, this barrier appears to be
compromised in the Rs1h knockout thereby allowing inﬁltration of
rAAV2 into the retina. The retinal cell type(s) which expressed and
secreted retinoschisin, however, was not determined in this study.
More recently, Park et al. (2009) have administered rAAV8 con-
taining the mouse Rs1h cDNA under the control of a 3.5 kb human
retinoschisin promoter to Rs1h knockout mice by intravitreal
injections. This approach was also reported to yield strong reti-
noschisin expression and secretion and signiﬁcant rescue of retinal
structure and function.
These studies indicate that the delivery of the normal RS1 gene
to retinal cells which do not express retinoschisin can promote
long-term rescue of retinal structure and function and greatly slow
photoreceptor degeneration. However, many XLRS patients harbor
missense mutations which allow the expression of the mutated
protein. Accordingly, wild-type retinoschisin expressed in these
cells by gene delivery could interact with the endogenously
expressed mutant retinoschisin diminishing the therapeutic effect
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expression, cellular localization and secretion of wild-type reti-
noschisin co-expressed with various disease-linked missense
mutants in culture cells (Dyka and Molday, 2007; Gleghorn et al.,
2010). These studies indicate that wild-type retinoschisin
undergoes protein folding, subunit assembly, and secretion largely
independent of the misfolded mutants. Hence, delivery of the
normal gene to XLRS patients expressing the mutant protein may
not be a problem although ideally this should be investigated
further in photoreceptors cells.
In considering future XLRS gene therapy clinical trials, both
routes of vector administration (subretinal and intravitreal) are
effective and feasible, although intravitreal injections may be the
optimal route of administration due to the fragile nature of the
retina of XLRS patients. However, it will be important to determine
if AAV8 or other AAV serotypes can efﬁciently penetrate the retina
of XLRS patients following intravitreal injections as demonstrated
in Rs1h knockout mice.
10. Conclusions and future directions
Since XLRS was ﬁrst reported over a century ago, signiﬁcant
progress has been made in the clinical diagnosis, genetic analysis,
and molecular and cellular basis for the disease. A wide assort-
ment of diagnostic tools has enabled clinical ophthalmologists to
accurately identify and monitor the disease progression. Clinical
diagnosis of XLRS has been greatly improved through the appli-
cation of SD-OCT to noninvasively image splitting and disruption
of the retinal layers. Following the initial discovery of the gene
responsible for XLRS, international teams of molecular geneticists
have identiﬁed over 190 different disease-causing mutations in
the RS1 gene, most of which lead to null alleles or non-functional
protein. Immunocytochemical and biochemical studies have
shown that retinoschisin is expressed in retinal neurons early in
development and secreted as a disulphide-linked oligomeric
protein complex which speciﬁcally binds to the surface of
photoreceptors and bipolar cells. A number of molecular mecha-
nisms by which missense mutations cause XLRS have been
elucidated. These include aberrant retinoschisin synthesis, protein
misfolding, and defective subunit assembly. Hemizygous Rs1h
knockout mice deﬁcient in retinoschisin have been generated and
shown to exhibit many of the characteristic features found in XLRS
patients including cystic cavities, disorganization of the
photoreceptor-bipolar synapse, reduction in b-wave of the ERG,
and progressive loss in rod and cone photoreceptor cells. Delivery
of the RS1 gene to Rs1h knockout mice using recombinant AAV has
resulted in a remarkable improvement in retinal structure and
function offering hope that this or related approaches may lead to
future clinical trials for XLRS and beneﬁt individuals affected with
the disease.
Although signiﬁcant progress has been made in understanding
XLRS, there are still many important unresolved issues that require
further study. The high resolution structure of retinoschisin
remains to be determined to validate and extend biochemical
analyses. The molecular mechanisms by which a deﬁciency in
retinoschisin results in the disorganization of the photoreceptor-
bipolar cell synaptic structure and function and the formation of
ﬂuid-ﬁlled cystic cavities require further study. Controversies
regarding the molecular nature of the components that interact
with retinoschisin need to be resolved tomore fully understand the
role of retinoschisin in retinal cell biology and physiology. Finally,
gene replacement studies successfully carried out on hemizygous
Rs1h knockout mice need to be extended to large animals to opti-
mize the route of delivery and site of injections prior to initiation of
human clinical trials.Acknowledgments
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